Join Professor Carol Pollock and experts from the Asia-Pacific region as they explore key challenges in the diagnosis and management of chronic kidney disease (CKD), including the role of newer antidiabetic agents.
This webcast was broadcast in English with a choice of subtitles and interpreters for the Q&A in Japanese and simplified Chinese.
A multidisciplinary (MDT) panel comprising a nephrologist, endocrinologist, cardiologist and primary care physician explore the benefits of collaborative working, supporting your clinical practice for better integrated care and outcomes for patients with CKD.
Suitable for Asia-Pacific-based nephrologists and other healthcare professionals involved in the CKD MDT.
Carol Pollock is an academic nephrologist with over 390 publications in basic research and clinical medicine and over 24,380 citations in esteemed medical journals. She is an inaugural Fellow of the Australian Academy of Health and Medical Sciences (2015), was conferred a Vice Chancellor’s Award for Excellence in Research Supervision (2012) and recognised as a ‘Distinguished Professor’ by the University of Sydney (2012).
She was the 2014 recipient of the Ministerial Award for Excellence in Cardiovascular Research. She was Scientific Chairman of the 2013 World Congress of Nephrology, held in Hong Kong. She is Chair of Kidney Health Australia, Chair of the Board of the New South Wales (NSW) Bureau of Health Information and Deputy Chair of the Board of the Australian Organ, Tissue and Transplant Authority. She is a member of the Australian National Health and Medical Research Council. Past health/research leadership roles include inaugural Chair of the NSW Agency for Clinical Innovation and immediate past Chair of the NSW Clinical Excellence Commission, remaining as a director of both organisations until April 2016. She was Chair of the Northern Sydney Local Health District Board since its inception in 2011 until Dec 2016. She was the inaugural Chair then co-Chair of the Research Advisory Committee of the Australian and New Zealand Society of Nephrology from 2016 until 2019. She was Director of Research Northern Sydney/Central Coast 2000–2011. She is on the scientific advisory committee of Australian Biotech Company Pharmaxis Pty Ltd, is a Director of Certa Therapeutics, Chairs the Health Advisory Committee for Linéaire Projects and is a Director of the Photobionics Institute. In November 2018 she was made an Ambassador of Business Events Sydney.
Carol Pollock has received honoraria for scientific presentations and/or advisory board attendance from AstraZeneca, Novartis, Chinook, Eli Lilly, Otsuka and Boehringer Ingelheim.
Professor Juliana Chan is Professor of Medicine and Therapeutics and Director of the Hong Kong Institute of Diabetes and Obesity at the Chinese University of Hong Kong, Prince of Wales Hospital. She is a physician scientist specialised in diabetes and clinical pharmacology. Since 1995, she has led a multidisciplinary team to establish the Hong Kong Diabetes Register as a research-driven quality improvement program, accompanied by a biobank for multiomic analysis in pursuit of precision medicine.
In 2007, her team designed the web-based Joint Asia Diabetes Evaluation (JADE) Technology to promote data-driven personalised care and collaborative research in Asia. Professor Chan has published 500 original articles and 20 book chapters. She is a committee member of international landmark studies and Hong Kong Government research and healthcare policies related to diabetes and non-communicable diseases. She is a recipient of the American Diabetes Association Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes and leads the Lancet Commission Report on Diabetes.
Juliana Chan discloses consultancy, lecture fees, and/or research support through institutions from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Hua Medicine, Lee Powder, Lilly, Merck, MSD, Novartis, Sanofi, Servier, Viatris and Pfizer. She is CEO (pro-bono) of the Asia Diabetes Foundation and Founding director of GemVCare.
David Sim is a senior consultant in the department of cardiology and director of the heart failure program at the National Heart Center Singapore. He is clinical associate professor at Duke National University of Singapore Graduate Medical School. His sub-specialty interest is in heart failure, mechanical circulatory support, and heart transplantation. He received a fellowship in heart failure and heart transplant at the Alfred Hospital, Melbourne, Australia. He is a member of the committee for the adult heart transplant program in the National Heart Centre Singapore and paediatric heart transplant program in KK Women’s and Children’s Hospital.
Professor Sim also has an interest in palliative care for advanced heart failure. He is the project director for the advanced care planning program in the National Heart Centre Singapore and honorary visiting consultant at Dover Park Hospice. Professor Sim plays an active role in various research projects and clinical trials and is the National Leader for Singapore for a few key global pharmacological heart failure trials. He is the current director of clinical trials and translational research.
He is currently the President of the Heart Failure Society of Singapore and is active in promoting disease awareness of heart failure in Singapore. In the Asia Pacific region, Professor Sim plays an active role setting up heart failure programs in countries such as Vietnam and Mongolia.
David Sim discloses consultancy, advisory board, and/or speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corpus, Medtronic, Merck, Menarini, Novartis, Otsuka, Pfizer, Roche, Servier, Transmedic, and Vifor Pharma. He also discloses a research grant from AstraZeneca.
Yook-Chin Chia is Head of the Department of Medical Sciences at Sunway University, Malaysia, and remains an honorary professor at the University of Malaya. She is currently the immediate past-president of the Malaysian Society of Hypertension and is the leader of the Malaysian Society of Hypertension-Sunway University Young Investigators Network and the president of the Malaysian Society for World Action on Salt and Sugar for Health, a non-governmental society to promote reduction of salt and sugar consumption in Malaysia.
Professor Chia is also a hypertension specialist for the European Society of Hypertension, and much of her clinical work and research is on hypertension and its related cardiovascular diseases. She participated in the JADE study on diabetes management and on the Diabetes-CKD study lead by Professor Juliana Chan. Her current research activities are with the HOPE-Asia Network, a group of hypertension specialists from Asia.
She is also a member of the editorial board for several journals and mentors young investigators on hypertension and its related cardiovascular diseases research.
Yook-Chin Chia discloses speaker honorarium from Abbott, Boehringer-Ingelheim, Omron, Medtronic Malaysia, Xepa-Sol Malaysia, Pfizer, Sanofi, Servier, and Novartis. She has received research grants from Pfizer and Omron.